S-1 plus intravenous and intraperitoneal Paclitaxel for gastric cancer with peritoneal metastasis.

Abstract

Peritoneal metastasis is the most frequent and life-threatening type of metastasis in patients with advanced gastric cancer. Despite recent advances in chemotherapeutic agents, any treatment, if administered only via the intravenous (IV) route, cannot satisfactorily control peritoneal metastasis in gastric cancer. Although intraperitoneal (IP) chemotherapy has been proposed as a treatment option, the clinical efficacy of IP chemotherapy for peritoneal lesions has not been examined in gastrointestinal cancer. One hundred patients with gastric cancer received combination chemotherapy of S-1 plus IV (50 mg/m(2)) and IP (20 mg/m(2)) paclitaxel (PTX) via a subcutaneously implanted peritoneal access port. S-1 was administered at 80 mg/m(2) per day for 14 consecutive days, followed by 7 days' rest. Radical gastrectomy was performed in a salvage setting when macroscopic curative resection was made feasible by the downstaging achieved by the combined chemotherapy. The median survival time (MST) of the patient sample was 23.6 months, with a 1-year survival of 80%. Combination chemotherapy of S-1 plus IV and IP PTX is well tolerated and very effective in patients with gastric cancer and peritoneal metastasis. Systemic chemotherapy combined with repeated IP administration of paclitaxel is a promising strategy for peritoneal carcinomatosis in gastrointestinal cancer.

• Authors: Joji Kitayama, Hironori Ishigami, Hironori Yamaguchi, Hiroharu Yamashita, Shigenobu Emoto, Shoichi Kaisaki
• Journal: Gastrointestinal cancer research : GCR (Gastrointest Cancer Res) Vol. 5 Issue 3 Suppl 1 Pg. S10-3 (May 2012) ISSN: 1934-7987 [Electronic] United States
• PMID: 22876333 (Publication Type: Journal Article)